Long-term benefit of vasodilating beta-blockers in acute myocardial infarction patients with mildly reduced left ventricular ejection fraction
PLOS One · 23.06.2025 · 20 (6) · e0326516
DOI: 10.1371/journal.pone.0326516 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 23.06.2025. Verfasst von Ki Yung Boo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Jeju National University Hospital, Jeju, Republic of Korea. Hauptthemen laut MEDLINE: Myocardial Infarction, Adrenergic beta-Antagonists, Stroke Volume, Vasodilator Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jeju National University Hospital.
Abstract (Originalsprache)
Beta-blockers have been considered the cornerstone of treatment for patients with acute myocardial infarction (AMI). However, long-term benefits of vasodilating beta-blockers remain uncertain. This study aimed to investigate the long-term clinical benefits of vasodilating beta-blockers compared to conventional beta-blockers in AMI patients with mildly reduced ejection fraction (mrEF). Among 13,624 patients who enrolled in the nationwide AMI database of South Korea, the KAMIR-NIH Registry, 2,662 AMI patients with mrEF, who were prescribed beta-blockers at discharge were selected for this study. The primary outcome was a composite of cardiac death, recurrent MI, or hospitalization for heart failure (HF) during 3-year follow up period. In the entire cohort, the use of vasodilating beta-blockers at discharge was associated with lower incidence of primary outcome at 3-year (hazard ratio [HR] 0.80; 95% confidence interval [CI], 0.62–0.98; P = 0.039) compared to the use of conventional beta-blockers at discharge. In the propensity score–matched (PSM) cohort, the use of vasodilating beta-blockers at discharge was also associated with a significantly lower incidence of primary outcome (HR, 0.66; 95% CI, 0.50–0.88; P = 0.004) compared to the use of conventional beta-blockers at discharge. Furthermore, in the PSM cohort, the use of vasodilating beta-blockers was associated with lower incidences of the cardiac death (HR, 0.60; 95% CI, 0.39–0.92; P = 0.020), hospitalization for HF (HR, 0.72; 95% CI, 0.46–0.98; P = 0.042), and all-cause death (HR, 0.67; 95% CI, 0.48–0.93; P = 0.017) compared to the use of conventional beta-blockers. However, no significant differences were observed between the groups in the incidences of recurrent MI (HR, 0.62; 95% CI, 0.34–1.14; P = 0.122), any revascularization (HR, 1.04; 95% CI, 0.76–1.42; P = 0.821), stroke (HR, 0.84; 95% CI, 0.44–1.60; P = 0.589), stent thrombosis (HR, 1.12; 95% CI, 0.40–3.11; P = 0.833). In AMI patients with mrEF, the use of vasodilating beta-blockers at discharge was associated with better long-term clinical outcomes compared to the use of conventional beta-blockers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Jeju National University Hospital, Jeju, Republic of Korea.
- Department of Internal Medicine, Jeju National University College of Medicine, Jeju, Republic of Korea.
- Department of Internal Medicine, Gyeonsang National University School of Medicine, Gyeongsang National University Hospital, Jinju, Republic of Korea.
- Keimyung University Dongsan Medical Center, Cardiovascular Medicine, Daegu, Republic of Korea.
- Pusan National University Hospital, Busan, Republic of Korea.
- Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea.
ORCID-Profile: Jae-Geun Lee, Song-Yi Kim, Seung-Jae Joo, Jin-Yong Hwang, Myung Ho Jeong
Förderung
- Jeju National University Hospital
Zitieren
APA
Boo, K. Y., Kim, M., Lee, J. G., Ko, G., Choi, J. H., Kim, S. Y., Joo, S. J., Hwang, J. Y., Hur, S. H., Cha, K. S., Jeong, M. H., & KAMIR-NIH registry investigators (2025). Long-term benefit of vasodilating beta-blockers in acute myocardial infarction patients with mildly reduced left ventricular ejection fraction. PLOS One, 20(6), e0326516. https://doi.org/10.1371/journal.pone.0326516
Vancouver
Boo KY, Kim M, Lee JG, Ko G, Choi JH, Kim SY, et al. Long-term benefit of vasodilating beta-blockers in acute myocardial infarction patients with mildly reduced left ventricular ejection fraction. PLOS One. 2025;20(6):e0326516. doi:10.1371/journal.pone.0326516
BibTeX
@article{Boo2025,
author = {Boo, Ki Yung and Kim, Miyeon and Lee, Jae-Geun and Ko, Geum and Choi, Joon Hyouk and Kim, Song-Yi and Joo, Seung-Jae and Hwang, Jin-Yong and Hur, Seung-Ho and Cha, Kwang Soo and Jeong, Myung Ho and KAMIR-NIH registry investigators, KAMIR-NIH registry investigators},
title = {Long-term benefit of vasodilating beta-blockers in acute myocardial infarction patients with mildly reduced left ventricular ejection fraction},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {6},
pages = {e0326516},
doi = {10.1371/journal.pone.0326516}
}
EUVIMED